Johnson&Johnson in the news
Global Healthcare Innovation Leader
Tamtam found 20 recent articles about Johnson&Johnson.
- Johnson & Johnson Delivered 'Immaculate' Prostate Cancer Data at ESMO. Here's Why Investors Should Care
Johnson & Johnson's JNJ-6143, an early-stage prostate cancer drug, delivered promising Phase 1 clinical trial results, showing a 75% overall response rate in difficult-to-treat patients.
- Dividend Roundup: Nvidia, Disney, Merck, Johnson & Johnson and more
This week's dividend roundup includes increased payouts from Merck and Disney, declarations from Nvidia and Nike, and upcoming announcements from Johnson & Johnson and S&P.
- Johnson & Johnson (JNJ) Reports Positive Phase 4 Tremfya Results in Psoriatic Arthritis
Johnson & Johnson announced positive Phase 4 clinical trial results for Tremfya in treating psoriatic arthritis, impacting its pharmaceutical portfolio while the stock remains overvalued.
- 3 ETFs That Give You Johnson & Johnson In Different Doses
Johnson & Johnson's new robotic surgery system installation is highlighted as the company faces profit margin pressure, while ETFs offer diversified investment options to mitigate single-stock risks.
- Johnson & Johnson submits FDA application for Caplyta in bipolar mania By Investing.com
Johnson & Johnson submitted an FDA application for Caplyta to treat manic or mixed episodes in adults with bipolar I disorder, supported by positive Phase 3 study results.
- Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenue
Johnson & Johnson demonstrates consistent and higher revenue growth compared to Pfizer, which faces volatility and a post-COVID-19 decline.
- Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenue
Johnson & Johnson maintains steady revenue growth through diverse pharmaceutical and medical tech products, while Novo Nordisk experiences flat revenue amid increasing competition in specialized therapies.
- Is J&J (NYSE:JNJ) Adding Positive CAPLYTA Study Results?
Johnson & Johnson reported positive late-stage trial results for CAPLYTA, indicating its effectiveness in rapidly improving manic episodes associated with bipolar disorder, leading to planned FDA submission.
- ETFs Are Net Sellers of Johnson & Johnson (JNJ) on Nov. 13
ETFs were net sellers of Johnson & Johnson stock on November 13, with a $24.8 million outflow, marking the second consecutive day of net selling from these funds.
- J&J agrees to buy eye-disease biotech Ollin, a $3.4 billion entry into retina drugs
Johnson & Johnson will acquire Ollin Biosciences for up to $3.4 billion to gain OLN324, a Phase 3 retinal antibody, marking its entry into the retinal disease market.
- Why Is Johnson & Johnson (JNJ) Showcasing New Blood Cancer Data At ASH?
Johnson & Johnson presented new clinical data on trispecific and T cell engaging antibodies for blood cancers at the 2026 ASH Annual Meeting.
- Johnson & Johnson Agrees to Buy Ollin Biosciences in Up to $3.33 Billion Deal
Johnson & Johnson will acquire Ollin Biosciences for up to $3.33 billion, as detailed alongside various financial and ESG ratings.
- J&J bets USD 3.3 billion on phase 3 eye drug
Johnson & Johnson acquires Ollin for USD 3.3 billion to gain its phase 3 eye drug OLN324 for wet AMD and diabetic macular oedema, with Blackstone Life Sciences co-funding development.
- J&J in discussions to buy Ollin Biosciences for up to $3.4B - report
Johnson & Johnson is reportedly in talks to acquire privately held biotech company Ollin Biosciences for up to $3.4 billion to expand its retinal disease treatments.
- J&J to buy eye disease biotech Ollin Biosciences for up to $3.3 billion
Johnson & Johnson will acquire Ollin Biosciences for up to $3.33 billion to strengthen its presence in eye disease therapies, particularly with the experimental drug OLN324 for diabetic macular edema and wet age-related macular degeneration.
- Johnson & Johnson To Acquire Ollin Biosciences And Late-Stage Bispecific Antibody With Best-In-Class Potential In Ophthalmology
Johnson & Johnson will acquire Ollin Biosciences and its late-stage bispecific antibody for ophthalmology.
- Johnson & Johnson entered into a definitive agreement to acquire Ollin Biosciences, Inc. for $3.3 billion.
Johnson & Johnson will acquire Ollin Biosciences for $3.3 billion to enhance its vision health portfolio.
- J&J strikes $2.2 billion buyout deal for eye disease biotech Ollin Biosciences
Johnson & Johnson will acquire Ollin Biosciences for an upfront payment of $2.2 billion to broaden its portfolio of eye disease treatments.
- J&J agrees to buy eye-disease biotech Ollin for $2.2 billion upfront, with Blackstone funding the late-stage trials
J&J acquires eye-disease biotech Ollin for an upfront payment of $2.2 billion, with Blackstone funding the Phase 3 trials of OLN324.
- Jim Cramer Says Johnson & Johnson Reflects Demand for Defensive Stocks
Johnson & Johnson shares hit new highs, driven by demand for defensive stocks and its acquisition of Ollin Biosciences.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Johnson&Johnson?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies